Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
20–50
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
First renal transplant
Participant eligible to receive valganciclovir prophylaxis as determined by the treating physician in accordance with the local approved product prescribing information (Cohort A only) or the participant is not expected to require any valganciclovir prophylaxis (Cohort B only) post-transplant
Participant has no history of known infertility
Participant is able and willing to provide semen samples
Participant agrees to utilize a barrier contraceptive throughout the study or for at least 90 days after cessation of valganciclovir treatment
You may not be if
Prior ganciclovir or valganciclovir within 3 months of enrollment
Organ transplant other than kidney
Participant has received an investigational new drug in the 3 months prior to transplant
Participant hs received an alkylating agent or other medications known to affect fertility/spermatogenesis
Participant is unlikely to be available for follow-up for the entire duration of the study (up to 52 weeks)
